Technology is one of the greatest invention of mankind and has gifted human beings with various boons. But with the advent of time technological advancement emerged as a great threat to human civilization. Technology provides wide benefits —catching serial killers, space exploration, diagnosing cancer, — but algorithms designed for one intention can be easily used for a direful one. For instance, gene editing technology called CRISPR (Clustered, Regularly Interspaced, Short Palindromic Repeat) is a breakthrough in healthcare industry, though it is commendable, it is feared that its deliberate or unintentional misuse might lead to far-reaching economic and national security implications. One of the major threats emerged with the introduction of CRISPR is the production of biological weapons. The ease of accessibility of this technology made bioweapons extremely cheaper as compared to missiles or other hi-tech warfare equipment. Considering the harmful impacts of bioweapons, governments across the world are investing in R&D activities to seek out methods to acknowledge diseases released by biological weapons such as smallpox, plague, cholera, and anthrax. Antibody vaccines effectively induce the desired medication with comparatively higher rates of success, leading to development of monoclonal antibodies (mAbs), which target a specific area or cell.Monoclonal antibodies (mAbs) are designed by hybridoma technology with an aim to trigger natural immune system. It is a flagship innovation in the molecular biology approved by the U.S. Food and Drug Administration (FDA) as an effective measure for disease treatment. In 2018, the global [FURL=https://www.industryarc.com/PressRelease/1670/Monoclonal-Antibodies-Market-Research-Analysis.html]Monoclonal Antibodies Market[/FURL] size valued at $101 billion and the growth is expected to propel at a CAGR of 8.5%, during the forecast period 2019-2025.
Browse Monoclonal Antibodies Market Report Link:
[FURL]www.industryarc.com/Report/16114/monoclonal-antibodies-market.html[/FURL]
Oncology Segment dominating the Monoclonal Antibodies Market Growth—
The growth in monoclonal antibodies market size is attributed to various factors such as increasing demand for antibodies to treat several health issues like respiratory diseases, oncology, autoimmune diseases, microbial diseases, inflammatory diseases, and ophthalmology disorders. Oncology segment is expected to generate major revenue in the monoclonal antibodies market, the key application segment is poised to propel at a CAGR of 8.67% through to 2025, owing to increasing incidences of cancer. Cancer is one of the leading causes of death worldwide, which has driven the focus on early detection and treatment of disease. According to Cancer Research UK, there were around 17 million new cases of cancer in 2018, and 9.6 million deaths worldwide in 2018.
Talk to one of our sales representative about the full report by providing your details in the link below:
[FURL]www.industryarc.com/support.php?id=16114[/FURL]
About IndustryARC: IndustryARC is a research and consulting firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.